Finance

Lists
GL9:FRA
Glanbia plc
€23.16
-6.61%
(-1.64) 1D
Aug 14, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GL9...
Open
€23.16
High
€23.16
Low
€23.16
Mkt. cap
5.27B
Avg. vol.
31.00
Volume
0.00
Dividend
1.93%
Quarterly dividend
€0.11
Ex-dividend date
Mar 19, 2026
P/E ratio
27.54
52-wk high
€26.00
52-wk low
€12.19
EPS
€0.84
No. of employees
5K
Open
€23.16
High
€23.16
Low
€23.16
Mkt. cap
5.27B
Avg. vol.
31.00
Volume
0.00
Dividend
1.93%
Quarterly dividend
€0.11
Ex-dividend date
Mar 19, 2026
P/E ratio
27.54
52-wk high
€26.00
52-wk low
€12.19
EPS
€0.84
No. of employees
5K
Profile
Glanbia plc is an Irish multinational nutrition company that owns several consumer brands that produce products such as food supplements and ingredients businesses. Glanbia is headquartered in Kilkenny, Ireland with over 5,500 employees in over 30 countries around the world. Glanbia’s consumer brands and ingredients are sold or distributed in over 130 countries. North America is the company’s largest market, and it also has a presence in Europe, Middle East, Asia-Pacific and Latin America. Glanbia's primary listing is on Euronext Dublin. Glanbia comprises three divisions: Glanbia Nutritionals, Glanbia Performance Nutrition and Joint Ventures. Given the company's origins in the co-operative movement, farmer-suppliers of the company retain a significant interest in the company. Tirlán remains the largest shareholder in Glanbia plc. as of 2022 and retains the right to nominate a number of non-executive directors to the board of the company in line with their mutual Relationship Agreement. Wikipedia
About Glanbia plc
CEOHugh McGuire
Employees4.96K
Founded1997
Headquarters-
SectorFood
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Oct 2025
Jan 2026
Apr 2026
Jul 2026
Revenue
1.01B
1.01B
1.04B
1.04B
Cost of goods sold
742.10M
742.10M
747.40M
747.40M
Cost of revenue
742.10M
742.10M
747.40M
747.40M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
155.35M
155.35M
180.40M
180.40M
Operating expense
175.05M
175.05M
196.65M
196.65M
Total operating expenses
917.15M
917.15M
944.05M
944.05M
Operating income
92.70M
92.70M
95.65M
95.65M
Other non operating income
-550.00K
-550.00K
-600.00K
-600.00K
EBT including unusual items
47.35M
47.35M
90.25M
90.25M
EBT excluding unusual items
88.65M
88.65M
94.05M
94.05M
Income tax expense
5.40M
5.40M
13.35M
13.35M
Effective tax rate
11.40%
11.40%
14.79%
14.79%
Other operating expenses
1.35M
1.35M
900.00K
900.00K
Net income
41.95M
41.95M
76.90M
76.90M
Net profit margin
4.15%
4.15%
7.40%
7.40%
Earnings per share
-
-
-
-
Interest and investment income
650.00K
650.00K
700.00K
700.00K
Interest expense
-8.00M
-8.00M
-8.05M
-8.05M
Net interest expenses
-7.35M
-7.35M
-7.35M
-7.35M
Depreciation and amortization charges
-
-
-
-
EBITDA
110.95M
110.95M
124.25M
124.25M
Gain or loss from assets sale
18.70M
18.70M
800.00K
800.00K
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps